Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Zhongnan Xu, Zhengzhi Liu, Yanli Wang, Jinling Xue, Tianying Chang, Yingzi Cui, Yang Cheng, Guangwen Liu, Wanhua Wang, Yannan Zhou, Shuang Yu, Qing Ren, Wei Yang, Xinyao Qu, Jiahui Chen, Xuesong Chen, Qiaohuan Deng, Haimiao Yang & Xiuge Wang. (2023) Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial. Expert Review of Clinical Pharmacology 16:4, pages 363-370.
Read now
Read now
Maliheh Safavi, Alireza Foroumadi & Mohammad Abdollahi. (2013) The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opinion on Drug Discovery 8:11, pages 1339-1363.
Read now
Read now
Jothydev Kesavadev, Arun Shankar, Gopika Krishnan & Sunitha Jothydev. (2012) Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. International Journal of General Medicine 5, pages 317-322.
Read now
Read now
Paul S. Jellinger. (2011) Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes. Postgraduate Medicine 123:1, pages 53-65.
Read now
Read now
Victoria K Gatenby & Mark T Kearney. (2010) The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert Opinion on Therapeutic Targets 14:12, pages 1333-1342.
Read now
Read now
Stanley Schwartz & Benjamin A Kohl. (2010) Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. Diabetes, Metabolic Syndrome and Obesity 3, pages 227-242.
Read now
Read now
Francisco Javier Ampudia-Blasco, Carlos Calvo Gómez, Xavier Cos Claramunt, Javier García Alegría, Esteban Jódar Gimeno, José Javier Mediavilla Bravo, Pedro Mezquita Raya, Jorge Navarro Pérez & Manel Puig Domingo. (2010) Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use. Expert Review of Endocrinology & Metabolism 5:6, pages 799-807.
Read now
Read now
Marta Letizia Hribal & Giorgio Sesti. (2010) Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 5:4, pages 495-505.
Read now
Read now
Carol H. Wysham. (2010) New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals. Postgraduate Medicine 122:3, pages 52-60.
Read now
Read now
Janet B. McGill. (2009) Insights from the Liraglutide Clinical Development Program—the Liraglutide Effect and Action in Diabetes (LEAD) Studies. Postgraduate Medicine 121:3, pages 16-25.
Read now
Read now
Articles from other publishers (33)
A. S. Ametov, I. E. Shokhin, E. A. Rogozhina, T. G. Bodrova, M. E. Nevretdinova, P. A. Bely, K. Ya. Zaslavskaya, D. V. Kurkin, K. N. Koryanova, E. S. Mishchenko & S. M. Noskov. (2023) Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide. Pharmacy & Pharmacology 11:3, pages 255-276.
Crossref
Crossref
Thomas Edward Conley, Katherine Lynsey White, Ashley Bond, Simon Harrison, John McLaughlin & Simon Lal. (2023) Emerging uses of glucagon-like peptide 1 (GLP-1) receptor agonists following ileal resection: literature review and case examples. Frontline Gastroenterology, pages flgastro-2023-102402.
Crossref
Crossref
Valeria Guglielmi, Silvia Bettini, Paolo Sbraccia, Luca Busetto, Massimo Pellegrini, Volkan Yumuk, Anna Maria Colao, Marwan El Ghoch & Giovanna Muscogiuri. (2023) Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications. Current Obesity Reports 12:2, pages 127-146.
Crossref
Crossref
G. A. Matveev, T. I. Golikova, A. A. Vasileva, E. V. Vasilieva, A. Y. Babenko & E. V. Shlyakhto. (2021) Comparison of the effects of liraglutide and sibutramine in obese patients. Obesity and metabolism 18:2, pages 218-228.
Crossref
Crossref
Eralda Asllanaj, Carolina Ochoa-Rosales, Marija Glisic, Jana Nano, Taulant Muka & Oscar H. Franco. 2019. Prognostic Epigenetics. Prognostic Epigenetics
289
324
.
Anirban Majumder. (2017) Beginning With Very Low Dose (0.2mg) Liraglutide in Indian Type 2 Diabetic Patients Appears Better Tolerated: Experience from Real Life Practice. Journal of Diabetes, Metabolic Disorders & Control 4:5.
Crossref
Crossref
Soumyabrata Roy Chaudhuri. (2016) LIRA 365 Plus-A Real World Experience of 19 Months Use of Liraglutide in the Obese Indian Type 2 Diabetic Subjects. Advances in Obesity, Weight Management & Control 5:4.
Crossref
Crossref
Marco Zavattaro, Marina Caputo, Maria Teresa Samà, Chiara Mele, Luisa Chasseur, Paolo Marzullo, Loredana Pagano, Maria Grazia Mauri, Maria Chantal Ponziani, Gianluca Aimaretti & Flavia Prodam. (2015) One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 50:3, pages 620-626.
Crossref
Crossref
Jorge F Elgart, Joaquin E Caporale, Lorena Gonzalez, Eleonora Aiello, Maximiliano Waschbusch & Juan J Gagliardino. (2013) Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Economics Review 3:1.
Crossref
Crossref
Kulvinder Kochar Kaur, Gautam Allahbadia & Mandeep Singh. (2013) Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs. Journal of Pharmacy and Nutrition Sciences 3:3, pages 178-190.
Crossref
Crossref
S Koppa Narayana, SK Talab & MA Elrishi. (2012) Liraglutide‐induced acute kidney injury. Practical Diabetes 29:9, pages 380-382.
Crossref
Crossref
Jorge F. Elgart, Lorena Gonzalez, Joaquin E. Caporale, Juan E. Valencia & Juan J. Gagliardino. (2012) Economic evaluation of type 2 diabetes treatment with saxagliptin in Colombia. Medwave 12:02, pages e5306-e5306.
Crossref
Crossref
Roger S. Mazze, Ellie S. Strock, Richard M. Bergenstal, Amy Criego, Robert Cuddihy, Oded Langer, Gregg D. Simonson & Margaret A. Powers. 2011. Staged Diabetes Management. Staged Diabetes Management
77
137
.
Kohei Kaku. (2011) Liraglutide for the treatment of diabetes mellitus in Japan. Diabetes Management 1:4, pages 451-463.
Crossref
Crossref
George Dailey. (2011) Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes. Clinical Therapeutics 33:6, pages 665-678.
Crossref
Crossref
R. Keith Campbell. (2011) Clarifying the Role of Incretin-Based Therapies in the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics 33:5, pages 511-527.
Crossref
Crossref
Richard B. Aguilar. (2011) Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success. Clinical Therapeutics 33:4, pages 408-424.
Crossref
Crossref
Fernando Ovalle. (2011) Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes. Clinical Therapeutics 33:4, pages 393-407.
Crossref
Crossref
Mark Stolar. (2011) Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care. The American Journal of the Medical Sciences 341:2, pages 132-140.
Crossref
Crossref
Lisa L. Ioannides-Demos, Loretta Piccenna & John J. McNeil. (2011) Pharmacotherapies for Obesity: Past, Current, and Future Therapies. Journal of Obesity 2011, pages 1-18.
Crossref
Crossref
R.C.L. Page. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
889
908
.
Jeff Unger. (2010) Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 85:12, pages S38-S49.
Crossref
Crossref
Jaime A. Davidson. (2010) Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clinic Proceedings 85:12, pages S27-S37.
Crossref
Crossref
Stanley S. Schwartz & Benjamin A. Kohl. (2010) Glycemic Control and Weight Reduction Without Causing Hypoglycemia: The Case for Continued Safe Aggressive Care of Patients With Type 2 Diabetes Mellitus and Avoidance of Therapeutic Inertia. Mayo Clinic Proceedings 85:12, pages S15-S26.
Crossref
Crossref
Jeffrey S. Freeman. (2010) A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 85:12, pages S5-S14.
Crossref
Crossref
David C. Klonoff. (2010) Incretin therapy for type 2 diabetes mellitus. Advances in Therapy 27:12, pages 881-894.
Crossref
Crossref
Louis Kuritzky. (2010) Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity. The American Journal of the Medical Sciences 340:2, pages 133-143.
Crossref
Crossref
F.J. Ampudia-Blasco, C. Calvo Gómez, X. Cos Claramunt, J. García Alegría, E. Jódar Gimeno, J.J. Mediavilla Bravo, P. Mezquita Raya, J. Navarro Pérez & M. Puig Domingo. (2010) Liraglutida en el tratamiento de la diabetes tipo 2:. Avances en Diabetología 26:4, pages 226-234.
Crossref
Crossref
Anne Peters. (2010) Incretin-Based Therapies: Review of Current Clinical Trial Data. The American Journal of Medicine 123:3, pages S28-S37.
Crossref
Crossref
Sunder Mudaliar & Robert R. Henry. (2010) Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function. The American Journal of Medicine 123:3, pages S19-S27.
Crossref
Crossref
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen & Michael EJ Lean. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet 374:9701, pages 1606-1616.
Crossref
Crossref
G. Aimaretti. (2014) Liraglutide: A once-daily human glucagon-like peptide-1 analogue. Journal of Endocrinological Investigation 32:8, pages 701-703.
Crossref
Crossref
Agostino Consoli. (2014) Liraglutide: ruolo nel trattamento del diabete di tipo 2. L'Endocrinologo 10:3, pages 102-105.
Crossref
Crossref